FDA Approves Longer Lengths of Medtronic’s Resolute Integrity Stent
February 25, 2013 — The U.S. Food and Drug Administration (FDA) has approved the 34 and 38 mm lengths of the Medtronic Resolute Integrity drug-eluting stent in diameters of 3, 3.5 and 4 mm with an indication for patients with diabetes.
Now available to cardiac catheterization laboratories nationwide, these new sizes of the Resolute Integrity stent enable the treatment of long coronary lesions, which are generally considered to span more than 27 mm.
Like the core sizes approved by the FDA in February 2012, the 34 and 38 mm lengths of the Resolute Integrity stent are indicated for treating the coronary artery disease of patients with diabetes, who commonly present with long lesions.
“Long coronary lesions and diabetes represent two distinct but often interrelated clinical challenges,” said Ronald Caputo, M.D., director of cardiac services and cardiology research at St. Joseph’s Hospital in Syracuse, N.Y. “The new sizes of the Resolute Integrity drug-eluting stent address both challenges in a single device. They have the potential to reduce procedure time and cost for clinicians and hospitals, as well as vessel trauma and contrast exposure for patients.”
FDA approval of the 34 and 38 mm lengths of the Resolute Integrity stent is based on data from the global RESOLUTE clinical program — specifically, a pre-specified analysis of one-year outcomes in patients with long coronary lesions who participated in the RESOLUTE U.S. and RESOLUTE Asia studies.
The analysis included data on 222 patients who received a 38 mm Resolute stent for the treatment of coronary lesions of no greater than 35 mm in length. The primary endpoint for the analysis was target lesion failure (TLF) — a composite of cardiac death, target vessel myocardial infarction and clinically-driven target lesion revascularization (TLR) — at one year of follow-up.
The long-lesion analysis met its primary endpoint, with a one-year TLF rate of 4.5 percent. Among the 38 percent of patients with diabetes, the one-year TLF rate was similarly low at 6 percent. The one-year rates of clinically driven TLR for all patients and the subset of diabetes patients were 1.4 percent and 2.4 percent, respectively.
For more information: www.medtronic.com
More like this
- Resolute Stent Shows Strong Performance in Heart Disease Patients With and Without Diabetes
- Medtronic Nets New Indications for Resolute Integrity Stent in Europe
- Medtronic’s Third-Generation Endeavor Resolute Drug-Eluting Stent Maintains Strong Safety Profile
- Medtronic’s Resolute DES Maintains Strong Efficacy, Safety in Long-Term Follow-up
- FDA Clears Medtronic Resolute Integrity Drug-Eluting Stent for Coronary Disease